Specifically, low-risk groups exhibited greater immune cell activity, including higher CD8+ T cell and immunostimulatory cell levels, supporting NecroticApop.Sig’s predictive robustness across multiple cancers and emphasizing its value in tailoring immunotherapy strategies. The gene discussed is CD8A; the disease is cancer.